Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01219777 · ClinicalTrials.gov registry record · Phase 1

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

A Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Ritu Salani.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT01219777: Completed Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Ritu Salani.

NCT01219777 is a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that has completed, run by Ritu Salani. The registered enrollment target is 9 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01219777, a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, has completed, sponsored by Ritu Salani.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive neoadjuvant chemotherapy (prior to surgical cytoreduction). Patients will then undergo surgery which will allow an objective measure of response to the above regimen as well as assessment of surgical outcomes.

Primary Outcome

To determine the maximum tolerated dose of carboplatin AUC5 administered Day 1 Cycles 1-4, weekly paclitaxel 60-80mg/m2 administered on Day 1, 8,and 15 for 3 weeks cycles 1-4, bevacizumab 15mg/kg administered Day 1 Cycles 1-3 prior to surgical intervention.

Conditions Studied

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

Interventions

  • DRUG Bevacizumab
  • DRUG Paclitaxel
  • DRUG carboplatin

Study Locations (1)

Ohio

  • The Ohio State University Medical Center - Columbus

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2010-09
Est. Completion 2015-05
Phase Phase 1
Ritu Salani

1 total trials

What the finished NCT01219777 record still lists

NCT01219777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.

NCT01219777 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT01219777 about?

NCT01219777 is a clinical study titled "Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian". The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive neoadjuvant chemotherapy (prior to s...

What is the current status of trial NCT01219777?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-09. Estimated completion is 2015-05.

What conditions does trial NCT01219777 study?

This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

What interventions are being tested in trial NCT01219777?

The interventions under investigation include: Bevacizumab (DRUG), Paclitaxel (DRUG), carboplatin (DRUG).

Who is sponsoring clinical trial NCT01219777?

This trial is sponsored by Ritu Salani, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01219777 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01219777's enrollment target sits among peer trials

9 313th of 322 higher than 9 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01219777, the US trial registry maintained by the National Library of Medicine. NCT01219777 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.